Nucleome Therapeutics Raises Oversubscribed £37.5 Million Series A Financing to Decode the Dark Matter of the Human Genome and Deliver First-in-class Precision Medicines

Oxford, UK, Oct. 19 (Korea Bizwire) – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion [...]